DMD: A Drug Target / Disease Biomarker (G1756)

Target Name: DMD

NCBI ID: G1756

Content of Review Report on DMD Target / Biomarker

DMD

DMD: A Drug Target / Disease Biomarker

DMD, also known as dopamine mesylated, is a protein that is expressed in the brain and is involved in the development and progression of several neurological disorders, including Parkinson's disease, addiction, and schizophrenia. It is a transmembrane protein that is composed of four extracellular domains and an intracellular domain. The intracellular domain is responsible for the protein's ability to interact with and modulate the activity of dopamine receptors.

One of the primary functions of DMD is to regulate the levels of dopamine in the brain. Dopamine is a neurotransmitter that plays a crucial role in the transmission of signals in the brain and is involved in a wide range of cognitive and motor functions. High levels of dopamine are associated with a range of positive behaviors, while low levels are associated with negative symptoms of disease. DMD helps to maintain the delicate balance of dopamine in the brain and is essential for the proper functioning of the brain.

In addition to its role in regulating dopamine levels, DMD is also involved in the development and progression of several neurological disorders. For example, studies have shown that DMD is overexpressed in the brains of individuals with Parkinson's disease, a progressive neurodegenerative disorder that is characterized by the loss of dopamine-producing neurons in the brain. This overexpression of DMD is thought to contribute to the progression of the disease and the development of its symptoms.

Another example of DMD's involvement in neurological disorders is its role in addiction. Studies have shown that DMD is involved in the modulation of dopamine release in the brain and that this modulation can be influenced by drugs of abuse. For example, individuals who smoke or consume drugs of abuse may increase their dopamine levels, which can lead to an increased risk of addiction. DMD's role in dopamine release is also thought to be involved in the development of addiction disorders.

In addition to its involvement in neurological disorders, DMD is also a potential drug target. Studies have shown that DMD can be inhibited by small molecules, such as those that bind to its intracellular domain. This suggests that DMD may be a useful target for the development of new treatments for a range of neurological disorders.

In conclusion, DMD is a protein that is involved in the development and progression of several neurological disorders, including Parkinson's disease, addiction, and schizophrenia. It is a transmembrane protein that is responsible for regulating the levels of dopamine in the brain and is a potential drug target for the development of new treatments for a range of neurological disorders. Further research is needed to fully understand the role of DMD in neurological disease and to develop effective treatments.

Protein Name: Dystrophin

Functions: Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission

The "DMD Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DMD comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets